Year archive

Enlivex Therapeutics Ltd. — 2024 filings

All 69 regulatory filings released by Enlivex Therapeutics Ltd. (ENLV) in 2024, sourced directly from the official regulator.

69 Filings

2024 Period

2024 filings (69)

Filing	Released	Lang
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis Regulatory Filings	2024-12-11	English
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis Report Publication Announcement	2024-12-11	English
Form 6-K - Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis Regulatory Filings	2024-12-03	English
Form 6-K - Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis Report Publication Announcement	2024-12-03	English
Form 6-K- Financial Statements as of September 30, 2024 Capital/Financing Update	2024-11-30	English
Form 6-K- Financial Statements as of September 30, 2024 Regulatory Filings	2024-11-30	English
x Adopts Bitcoin Treasury Reserve Strateg Regulatory Filings	2024-11-20	English
x Adopts Bitcoin Treasury Reserve Strateg Report Publication Announcement	2024-11-20	English
Form 6-K - Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis Regulatory Filings	2024-11-14	English
Form 6-K - Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis Report Publication Announcement	2024-11-14	English
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis Regulatory Filings	2024-11-12	English
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis Regulatory Filings	2024-11-12	English
Results of a meeting held on November 7, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-11-09	English
Results of a meeting held on November 7, 2024 Report Publication Announcement	2024-11-09	English
Immediate Report of adjourned meeting to be held on November 7,2024 Proxy Solicitation & Information Statement	2024-10-31	English
Immediate Report of adjourned meeting to be held on November 7,2024 AGM Information	2024-10-31	English
The Annual Meeting will be reconvened on Thursday, November 7, 2024 AGM Information	2024-10-31	English
The Annual Meeting will be reconvened on Thursday, November 7, 2024 Report Publication Announcement	2024-10-31	English
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis Regulatory Filings	2024-10-30	English
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis Report Publication Announcement	2024-10-30	English
Amended and Restated Compensation Policy for Company Office Holders Remuneration Information	2024-10-15	English
Amended and Restated Compensation Policy for Company Office Holders Report Publication Announcement	2024-10-15	English
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis Regulatory Filings	2024-09-26	English
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis Report Publication Announcement	2024-09-26	English
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis Regulatory Filings	2024-09-24	English
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis Report Publication Announcement	2024-09-24	English
Immediate Report of Meeting to be held on October 31, 2024, proxy statement Proxy Solicitation & Information Statement	2024-09-11	English
Immediate Report of Meeting to be held on October 31, 2024, proxy statement AGM Information	2024-09-11	English
Immediate Report of Meeting to be held on October 31, 2024, proxy statement AGM Information	2024-09-11	English
FINANCIAL STATEMENTS AS OF JUNE 30, 2024 Capital/Financing Update	2024-08-31	English
FINANCIAL STATEMENTS AS OF JUNE 30, 2024 Report Publication Announcement	2024-08-31	English
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis Regulatory Filings	2024-07-23	English
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis Report Publication Announcement	2024-07-23	English
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra in up to 46 Patients with Thumb Osteoarthritis Regulatory Filings	2024-06-24	English
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra in up to 46 Patients with Thumb Osteoarthritis Report Publication Announcement	2024-06-24	English
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 Regulatory Filings	2024-06-20	English
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 Report Publication Announcement	2024-06-20	English
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis Regulatory Filings	2024-06-17	English
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis Report Publication Announcement	2024-06-17	English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 Interim / Quarterly Report Q1 2024	2024-06-15	English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 Report Publication Announcement Q1 2024	2024-06-15	English
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis Regulatory Filings	2024-06-03	English
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis Report Publication Announcement	2024-06-03	English
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering Regulatory Filings	2024-05-30	English
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering Report Publication Announcement	2024-05-30	English
Prospectus Supplement Capital/Financing Update	2024-05-30	English
Prospectus Supplement Report Publication Announcement	2024-05-30	English
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering Capital/Financing Update	2024-05-28	English
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering Report Publication Announcement	2024-05-28	English
20F FOR 2023 Annual Report FY 2023	2024-05-01	English
20F FOR 2023 Report Publication Announcement	2024-05-01	English
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events Regulatory Filings	2024-04-29	English
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events Report Publication Announcement	2024-04-29	English
Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis Regulatory Filings	2024-04-22	English
Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis Report Publication Announcement	2024-04-22	English
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis Regulatory Filings	2024-04-16	English
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis Report Publication Announcement	2024-04-16	English
To Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis Regulatory Filings	2024-04-12	English
To Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis Report Publication Announcement	2024-04-12	English
Form 6-K- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis Regulatory Filings	2024-04-11	English
Form 6-K- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis Regulatory Filings	2024-04-11	English
6-k -FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 Annual Report FY 2023	2024-03-30	English
6-k -FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 Report Publication Announcement	2024-03-30	English
Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method Regulatory Filings	2024-02-07	English
Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method Report Publication Announcement	2024-02-07	English
6K-Court approved the Company’s motion to extend the share repurchase program until June 30, 2024 Regulatory Filings	2024-01-22	English
6K-Court approved the Company’s motion to extend the share repurchase program until June 30, 2024 Report Publication Announcement	2024-01-22	English
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Os Regulatory Filings	2024-01-17	English
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Os Report Publication Announcement	2024-01-17	English

Filings by year

2026 45 filings
2025 63 filings
2024 69 filings
2023 55 filings
2022 62 filings
2021 73 filings
2020 78 filings
2019 40 filings